Glenmark Pharmaceuticals Limited — Financials & Forensics
Sector: Healthcare · NSE: GLENMARK · BSE: 532296 · ISIN: INE935A01035
08 May 2026
Add GLENMARK to your watchlist — all of this, automated.
Sign in with GoogleAnnual P&L snapshot
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue from operations | ₹12,305 Cr | ₹12,990 Cr | ₹11,813 Cr | ₹13,322 Cr | ₹16,983 Cr |
| EBITDA | ₹2,320 Cr | ₹2,278 Cr | ₹1,195 Cr | ₹2,351 Cr | ₹4,572 Cr |
| EBITDA margin | 18.9% | 17.5% | 10.1% | 17.6% | 26.9% |
| Profit after tax | ₹994 Cr | ₹377 Cr | ₹-1,831 Cr | ₹1,047 Cr | ₹1,362 Cr |
Deeper analysis
Recent filings by Glenmark Pharmaceuticals Limited
-
Glenmark advances Multi-Country Phase 3 Clinical Trial of Trastuzmab rezetecan in Platinum-Resistant
02 Jul 2026 · General Update
-
General Updates
30 Jun 2026 · Regulatory Compliance
-
Intimation of schedule of analyst / institutional investor meeting
25 Jun 2026 · General Update
-
Intimation of Closure of Trading Window
25 Jun 2026 · Regulatory Compliance
-
Press Release
17 Jun 2026 · General Update
Never miss a filing again
About Glenmark Pharmaceuticals Limited on Indian Stock Alerts
Indian Stock Alerts tracks Glenmark Pharmaceuticals Limited's SEBI / exchange filings in real time. Every quarterly result, audited annual report, shareholding pattern update, insider trade and corporate announcement is automatically parsed and surfaced as a structured data point — with a link back to the underlying filing.
Data points refreshed daily include closing price, 1Y change, market cap, P/E, ROE, dividend yield, RPT volume, audit / governance / accrual flags. Quarterly results numbers refresh within minutes of the company filing them with BSE / NSE.